FXR |
Liver |
Downregulates triglyceride, fatty acid and cholesterol biosynthesis |
|
|
Increases fatty acid oxidation |
|
|
Increases lipolysis |
|
|
Decreases gluconeogenesis |
|
|
Promotes glycogen synthesis |
|
|
Exerts antiinflammatory and antifibrotic effects |
|
|
Promotes liver regeneration |
|
Pancreas |
Stimulates insulin secretion |
|
Intestine |
Stimulates bile acid reabsorption |
|
|
Stimulates FGF19 production |
|
|
Exerts antiinflammatory and antifibrotic effects |
|
Skeletal muscle and adipocytes |
Increases glucose uptake and insulin sensitivity |
|
|
Increases adipogenesis and lipid storage |
|
Kidney |
Exerts antiinflammatory and antifibrotic effects |
|
Vascular smooth muscle cells |
Exerts antiatherogenic effects |
|
Vascular endothelial cells |
Exerts antihypertension effects |
|
Macrophages |
Exerts antiinflammatory effects |
TGR5 |
Liver sinusoidal endothelial cells |
Vasodilation |
|
Cholangiocytes |
Exerts antiapoptotic and antiinflammatory effects |
|
Macrophages |
Exerts antiinflammatory effects |
|
Gallbladder |
Gallbladder filling |
|
Pancreas |
Stimulates insulin secretion |
|
Skeletal muscle and brown adipose tissue |
Increases energy expenditure |
|
Intestinal L cells |
Stimulates GLP-1 secretion |
|
Enteric neurons |
Promotes motility or peristalsis |
|
Primary spinal afferent and sensory neurons |
Induces neuronal hyper excitability and release of GRP (gastrin-releasing peptide) |